Former Disney CEO Named to Masimo’s Board of Directors

Former Walt Disney Company CEO Bob Chapek has been appointed to Masimo’s Board of Directors.

Chapek was CEO of The Walt Disney Company from February 2020 to November 2022, leading Disney through the global COVID-19 pandemic and recovery. Under his leadership, Disney strategically realigned its media and entertainment divisions, expanded the scale and global reach of its streaming services, made transformative changes to its parks and resorts worldwide, and leveraged new and innovative technologies to bring stories to life in more immersive and impactful ways.

“We are honored to have Bob join the board. As we execute our hospital to home strategy, we expect to benefit greatly from Bob’s role on our board,” Masimo Chairman/CEO Joe Kiani said.
 
Before becoming CEO, Chapek was chairman of Disney Parks, Experiences and Products since the segment’s creation, and prior to that was chairman of Walt Disney Parks and Resorts. At Disney Parks, he implemented strategies to improve the guest experience by balancing demand at the parks, integrating new franchises at locations around the world. As head of Disney Consumer Products, he led a period of transformation in the worlds of play, storytelling, and learning. Chapek also was president of Distribution for The Walt Disney Studios, where he managed the company’s film content distribution strategy across multiple platforms, and later as president of Walt Disney Studios Home Entertainment, where he led the organization to record-setting performances and played a key role in the commercialization of the Studio’s film business.
 
Before joining Disney, Chapek worked in brand management at H.J. Heinz Company, and in advertising at J. Walter Thompson. He earned a degree in microbiology from Indiana University Bloomington, and an MBA from Michigan State University.
 
“I am thrilled to join the Masimo Board,” Chapek stated. “I look forward to helping advance the company’s growth by leveraging their core technologies in the consumer and consumer health spaces.”
 
Irvine, Calif.-based Masimo is a global medical technology company that develops and produces various monitoring technologies, including measurements, sensors, patient monitors, and automation and connectivity solutions. Its mission is to improve life, improve patient outcomes, and reduce care costs. Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, introduced in 1995, has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies.¹ Masimo SET has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,² improve CCHD screening in newborns,³ and, when used for continuous monitoring with Masimo Patient SafetyNet in post-surgical wards, reduce rapid response team activations, ICU transfers, and costs.^4-7 Masimo SET is estimated to be used on more than 200 million patients in hospitals and other healthcare settings worldwide,⁸ and is the primary pulse oximetry at nine of the top 10 hospitals as ranked in the 2022-23 U.S. News and World Report Best Hospitals Honor Roll.⁹ 

In 2005, Masimo introduced rainbow Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb), oxygen content (SpOC), carboxyhemoglobin (SpCO), methemoglobin (SpMet), Pleth Variability Index (PVi), RPVi (rainbow PVi), and Oxygen Reserve Index (ORi). In 2013, Masimo introduced the Root Patient Monitoring and Connectivity Platform, built to be as flexible and expandable as possible to facilitate the addition of other Masimo and third-party monitoring technologies; key Masimo additions include Next Generation SedLine Brain Function Monitoring, O3 Regional Oximetry, and ISA Capnography with NomoLine sampling lines. Masimo’s continuous and spot-check monitoring Pulse CO-Oximeters includes devices designed for use in various clinical and non-clinical scenarios, including tetherless, wearable technology, such as Radius-7, Radius PPG, and Radius VSM, portable devices like Rad-67, fingertip pulse oximeters like MightySat Rx, and devices available for use both in the hospital and at home, such as Rad-97. Masimo hospital and home automation and connectivity solutions are centered around the Masimo Hospital Automation platform, and include Iris Gateway, iSirona, Patient SafetyNet, Replica, Halo ION, UniView, UniView :60, and Masimo SafetyNet. Its health and wellness solutions includes Radius Tº, Masimo W1, and Masimo Stork. 
 
RPVi has not received U.S. Food and Drug Administration 510(k) clearance and is not available for sale in the United States. The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.
 
References
¹ Published clinical studies on pulse oximetry and the benefits of Masimo SET® can be found on our website at http://www.masimo.com. Comparative studies include independent and objective studies which are comprised of abstracts presented at scientific meetings and peer-reviewed journal articles.
² Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.
³ de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;Jan 8;338.
⁴ Taenzer A et al. Impact of pulse oximetry surveillance on rescue events and intensive care unit transfers: a before-and-after concurrence study. Anesthesiology. 2010:112(2):282-287.
⁵ Taenzer A et al. Postoperative Monitoring – The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.
⁶ McGrath S et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.
⁷ McGrath S et al. Inpatient Respiratory Arrest Associated With Sedative and Analgesic Medications: Impact of Continuous Monitoring on Patient Mortality and Severe Morbidity. J Patient Saf. 2020 14 Mar. DOI: 10.1097/PTS.0000000000000696.
⁸ Estimate: Masimo data on file.
⁹ http://health.usnews.com/health-care/best-hospitals/articles/best-hospitals-honor-roll-and-overview.